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Vitamin D is a class of hormones necessary to maintain normal 
physiological activities of the body. A large number of studies have shown 
that vitamin D, as a fat-soluble vitamin, is not only related to calcium and 
phosphorus metabolism, but also closely related to immune regulation, 
humoral regulation, cell cycle and so on. Systemic Lupus erythema-Tosus 
(SLE) is a specific autoimmune diffuse connective tissue disease that 
causes tissue and organ damage under the joint action of multiple factors 
such as environment and heredity. Among many factors, the vitamin D 
metabolism	pathway	gene	is	particularly	important	for	its	influence.	Some	
literature has shown that the genetic polymorphism of vitamin D metabolic 
pathway genes is correlated with SLE. Therefore, by referring to relevant 
literature,	 this	paper	 summarized	 the	progress	 in	 the	 research	on	 the	
mechanism of genetic polymorphism of vitamin metabolism pathway genes 
and the development of SLE.
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1. Introduction
Recent studies have shown that serum vitamin D de-
ficiency in patients with SLE [1]. Gao et al. conducted a 




the incidence of SLE [2]. Some animal experiments have 
also shown that moderate vitamin D can reduce the lev-
els of urine protein, impaired joint function and reduce 
the damage of renal function in lupus rats [3]. In the study 
of genetic level, Luo Xiongyan, Liu Junlin et al. further 
studied the genetic polymorphism of vitamin D metabolic 
pathway genes and SLE [4-5].	In	foreign	literature,	Ozaki,	
Huang et al also studied the correlation [6-7]. In this paper, 
we review the research progress on the genetic polymor-
phism of vitamin D metabolic pathway related to the 
pathogenesis and development of SLE.
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2. Research Progress of Systemic Lupus Ery-
thematosus (SLE)
2.1 Pathogenesis
Systemic lupus erythematosus (SLE) is an autoimmune 
disease that often affects women of childbearing age [8], 
with a high incidence, multiple system, multiple organs 
involved, repeated attacks and other characteristics [9-10]. 
At present, its pathogenesis is not fully understood, main-
ly including the formation of immune complex which is 
involved in multiple organ damage, the production of au-
toantibodies, the over-activation of T cells and B cells and 
other abnormal regulation of the immune system [11-13].
2.2 Clinical Manifestations
The clinical symptoms of SLE are more complex, 
mainly including respiratory system damage, kidney dam-
age symptoms, fever, facial erythema, joint pain and so 
on. In mild cases, only arthralgia or facial rashes are pres-
ent, while in severe cases, early life-threatening severe 
thrombocytopenia, neuropsychiatric lupus, progressive 
lupus nephritis, and alveolar bleeding occur [10,14].
2.3 Common Treatment Methods
The drugs for clinical treatment of SLE mainly include 
hormones and immunosuppressants, which are known as 
Stand of Care (SOC). Glucocorticoids are often used in 
combination with prednisone and metasone. In the acute 
stage of the onset of SLE, a large amount of glucocor-
ticoids may pull the patient back from the line of life or 
death, but adverse reactions may occur [15].
3. Single Nucleotide Polymorphism and SNP 
Detection Techniques
Single nucleo tide polymorphism (SNP) refers to the 
transformation, transposition, insertion and deletion of a 
specific nucleotide position in the DNA of the genome, 
and the frequency of at least one allele in the population 
is not less than 1%. Although the genetic code consists of 
four bases, an SNP is usually just a biallelic, or dimorphic 
genetic variation, in which two different bases are present 
at that location. If the four bases mutate randomly, the 
transversions in the SNP should be twice as much as the 
transversions, but the chance of four bases mutating is not 
equal. In fact, the conversion accounts for a higher pro-
portion in the SNP. Through the application of sequencing 
and gene mutation research technology, a large number 
of SNPs have been obtained, and a common database has 
been	established.	The	development	of	efficient	SNP	analy-
sis techniques has expanded the scope of the study from a 
small number of variants associated with a particular dis-
ease to genetic markers corresponding to multiple varia-
tion types within multiple genes. SNP analysis techniques 
are mainly divided into two categories according to their 
research objects, namely: (1) analysis of unknown SNPs, 
that	is,	finding	unknown	SNPs	or	determining	the	relation-
ship between an unknown SNP and a genetic disease; (2) 
Analysis of known SNPs, i.e. detection of genetic diversi-
ty of SNPs in different populations or genetic diagnosis of 
genetic diseases with known pathogenic genes in clinical 
practice. In practical application, many methods for de-
tecting unknown SNPs can also be used to detect known 
SNPs, and methods for detecting known SNPs can also 
be used to screen unknown SNPs, and then sequencing 
method can be used to determine the types and locations 
of SNP mutations after screening. The following introduc-
tion of SNP analysis commonly used method, in addition 
to the mutation mismatch amplification test (MAMA), 
SNPshotTM	GeneScan	and	allele	specific	oligonucleotide	
fragment analysis (ASO) can only detect known muta-
tions, other methods can be used in the analysis of two 
kinds of SNP detection, the experimenter can according 
to their own needs and choose to suit the condition of the 
experiment	equipment,	simple	and	efficient,	economy	or	
mass detection method [16]. 
4. Research Progress on Vitamin D Metabolic 
Pathway
VD occurs in a variety of forms in the body, including 
25-hydroxyvitamin D (25-(OH)D) and 1, 25-dihydroxyvi-
tamin D (1,25- (OH)).2D) [17],	25-(OH)D	is	first	formed	by	
the	hydroxylation	of	25-α-hydroxylase	encoded	by	CY-
P2R1 gene in liver, and 25-hydroxyvitamin D is consid-
ered to be the most representative biomarker of the overall 
level of VD in human body [18]; After that, it is formed 
by	hydroxylating	1-α	hydroxylase	encoded	by	CYP27B1	
gene in the kidney [19], 1, 25 - (OH)2D is the active form 
of VD,1,25-(OH).2D forms 1,24,25-(OH) under the ac-
tion of 24 hydroxylase encoded by CYP24A1 gene3,24 
hydroxylases also combine 25(OH)D and 1,25-(OH).2D 
degrades and plays a negative feedback regulating role [20]. 
Vitamind Binding protein (VDBP), edited by VDBP gene, 
binds to vitamin D and promotes vitamin D transport in 
the liver and kidney.1, 25 (OH)2D exerts biological ef-
fects by binding to the VitaminD receptor (VDR), which 
is encoded by the VDR gene.The vitamin D pathway gene 
is the conversion of VD to 1,25-(OH)2. The genes that 
play a regulatory role in the process of D mainly include 
CYP2R1, CYP27B1, CYP24A1, VDBP and VDR. The 
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abnormal expression of vitamin D metabolic pathway 
genes may affect the level of vitamin D, thus affecting the 
play	of	biological	efficacy	[21].
5. Vitamin D Metabolic Pathway Gene Poly-
morphism and SLE
5.1 CYP2R1 Gene Polymorphism and SLE
CYP2R1 gene is located in human chromosome 11 
P15.2, with a span of 15.5 KB and 5 exons [22]. CYP2R1 
gene encodes the 25-hydroxylase of vitamin D (CYP2R1), 
which is present in the liver microsomal cytochrome 
P450. It is a member of the 2 subfamilies of the P450 fam-
ily and is composed of 501 amino acids [23]. The main role 
of CYP2R1 is the 25-position hydroxylation of vitamin 
D in the liver to produce 25-hydroxyvitamin D(25-(0H)
D), which is the main product of the vitamin D metabolic 
cycle. Genome-wide Association Studies (GWAS) deter-
mined that CYP2R1 SNPs were associated with vitamin 
D	levels,	and	some	previous	studies	also	showed	a	signifi-
cant association between CYP2R1 variants and 25-(0H)D 
levels [24-25].	It	was	also	confirmed	by	Wang	et	al	that	both	
CYP2R1 and CYP27A1 played a role in the 25-hydroxyl-
ation of vitamin D [24], but CYP2R gene plays a dominant 
role, and CYP27A1 is a secondary factor in the synthesis 
of 25-(0H)D.
A large number of studies have shown that single 
nucleotide polymorphisms of CYP2R1 are significantly 
associated with many diseases. The occurrence of atypical 
vitamin	D	deficiency	rickets	was	related	to	the	mutation	
of CYP2R1 gene. Xu et al. found that CYP2R1 locus 
rs10766197 was significantly correlated with low serum 
vitamin D content in Uyghur population [26]. Wang et al. 
confirmed	through	comparative	studies	that	CYP2R1	lo-
cus rs10766197 was significantly correlated with serum 
25-(0H)D level in patients with type II diabetes [27]. At the 
same time, CYP2R1 gene polymorphism was found to 
be	significantly	associated	with	the	susceptibility	to	type	
I diabetes, and the low expression of CYP2R1 may be 
associated with the decreased 25-(0H)D concentration in 
blood of patients with type I diabetes. The CYP2R1-in-
duced product 25-(0H)D is associated with susceptibility 
to a variety of cancers, including pancreatic cancer and 
breast cancer. Sheng et al. found that the high expression 
of CYP2R1 gene was significantly correlated with the 
relapse-free survival rate of breast cancer through a large 
number of studies and analyses [28]. The loci rs10741657, 
rs2060793 and rs12794714 in CYP2R1 gene are associ-
ated with 20% to 30% susceptibility to pancreatic cancer.
In	GWAS,	these	SNPs	of	CYP2R1	were	significantly	cor-
related with 25-(0H)D levels.
In addition to being associated with these diseases, a 
large number of loci of the CYP2R1 gene also indicate an 
association with 25-(0H)D levels.25-(0H)D is the main 
form of vitamin D in the blood. At present, the level of 
vitamin D in the body is mainly measured by detecting 
serum 225-(0H)D in clinical practice [29]. Studies have 
shown	that	there	are	widespread	problems	of	insufficient	
or	deficient	serum	25-(0H)D	levels	in	patients	with	SLE	
[30], Squance et al. found that the serum level of 25-(0H)
D in SLE patients was significantly lower than that in 
normal healthy people by comparing the serum of 80 
patients with SLE and 41 healthy people with normal 
physical examination [31]. Serum 25-(0H)D level plays an 
important role in the pathogenesis of SLE, and is related 
to the pathogenesis of SLE, and can be used as a clinical 
indicator to judge the severity of SLE disease [36]. Studies 
have found that low 25-(0H)D level in patients with SLE 
is associated with high activation of B cells and high ex-
pression	of	IFN-α	signal,	as	well	as	high	anti-dsDNA	and	
immunoglobulin levels [32].	This	finding	provides	evidence	
that low 25-(0H)D levels may trigger the production of 
autoantibodies, thereby increasing an individual’s risk 
of developing autoimmune diseases. On this basis, it can 
be concluded that CYP2R1 gene further affects SLE by 
affecting the liver 25 hydroxylation of vitamin D in the 
vitamin D metabolic pathway, thereby affecting the blood 
25-(0H)D level.
5.2 VDBP Gene Polymorphism and SLE
Vitamin D Binding Protein (VDBP) is encoded by the 
VDBP gene. VDBP is a plasma Protein that can play a 
variety	of	roles	and	is	synthesized	in	a	variety	of	tissues	
in the body, but mainly in the liver.It was successfully 
isolated in 1959 and was originally called group-specif-
ic conponent-Gc globulin because of its immunological 
characteristics [33]. Later, Gc protein and VDBP were 
found to be the same protein through multiple studies 
[34]. Genes encoding VDBP GC locates to the long arm of 
chromosome 4 q11 - q12, at present there are more than 
2000 SNPS are found the gene, VDBP with vitamin D has 
a close connection between VDBP in maintaining serum 
vitamin D levels, adjust the bioavailability of vitamin 
D, vitamin D activity and end the response to vitamin D 
plays and important role [35]. Among them, VDBP plays a 
very important role in vitamin D pinocytosis, and its gene 
polymorphism will affect vitamin D level and activity [36]. 
In addition, studies have shown that VDBP also plays a 
very important role in the vitamin D metabolic pathway, 
and its polymorphism is related to the immune response 
and the ability to bind vitamin D and its derivatives.
There are many studies on the association between sin-
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gle nucleotide polymorphism of VDBP gene and disease 
at home and abroad [37]. VDBP is associated with lung dis-
ease, liver disease, obesity, bone tissue disease, diabetes 
and many other diseases [38-40]. At present, domestic and 
foreign studies on VDBP encoding genes mostly focus 
on rs2282679(A/C), rs45889(C/A) and rs7041(T/G), and 
studies have found that rs2282679(A/C) polymorphism is 
correlated with vitamin D level [41-43], and SNP rs2282679 
is associated with bone metabolic diseases, obesity, heart 
and lung diseases, etc [38]. Regulla et al. found that VDBP 
gene polymorphism was correlated with Graves’ disease 
[44]. Wang Gaoshuai et al. found that the SNP locus rs7041 
of VDBP was closely related to obesity [45]. However, 
at present, the role of VDBP gene polymorphism in the 
pathogenesis of SLE is still unclear, and there are no 
large-scale clinical studies and reports on the association 
between SLE patients and VDBP gene polymorphism, so 
it	still	needs	to	be	verified	by	subsequent	experiments.
5.3 CYP27B1 Gene Polymorphism and SLE
CYP27B1	gene	is	 the	encoding	gene	of	1-α-hydroxy-
lase, which exists on the long arm of human chromosome 
12 (12q13.1-q13.3). It consists of 9 exons and 8 introns, 
and is a single-copy gene. Its full length cDNA is 4.8 KB, 
encoding 508 amino acid polypeptide [46-47], a member of 
the	P450	family	of	enzymes,	encodes	1-α	hydroxylase.
α-hydroxylase	 catalyzes	 25-(0H)D	 to	 form	 1,25-
(0H)2A	rate-limiting	enzyme	of	D	whose	main	function	is	
to catalyse the hydroxylation and activation of 25-(0H)D 
in the proximal convoluted tubules and rectus and convert 
it to its active form 1,25-(0H).2D [48-50]. Panda and Zhang 
Zengli	et	al	 found	 that	 the	changes	of	1-α-hydroxylase	
activity were correlated with 1,25-(0H) in plasma and 
local area. 2D levels were associated with immune sys-
tem dysfunction, and no active vitamin D was found in 
animals targeted with the CYP27B1 gene [51-53]. Multiple 
literature reports, 1,25-(0H)2D has a direct effect on both 
T and B cells, not only promoting the production of vari-
ous	inflammatory	cytokines,	but	also	inducing	regulatory	
T	cells	to	participate	in	a	“off”	inflammatory	response.	On	
this basis, some studies show that [51] Vitamin D is mainly 
involved in SLE by increasing the number of regulatory T 
cells and producing anti-proliferation effects. Therefore, 
it can be concluded that CYP27B1 single nucleotide poly-
morphism is closely related to the occurrence and devel-
opment of SLE.
5.4 Calcium-phosphorus Regulation of Vitamin D 
in SLE
Coexistence of vitamin D and vitamin A in cod liver oil, 
animal tissues and within the human body skin contains 
cholesterol, A precursor of vitamin D3 7 - dehydrogenation 
after sunlight into vitamin D, vitamin D with biological 
activity of 1, 25 - (OH) 2 D3 form play A role, the calcium, 
phosphorus, and children’s bone growth has very important 
meaning. Studies have reported that the level of 1,25- (OH) 
2D3 is positively correlated with bone mineral density in 
patients with SLE, and the incidence of SLE combined 
with osteoporosis is 1.4% ~ 68% [54-46], the larger span was 
due to differences in genetic background, ethnicity, age, 
and disease activity, and postmenopausal women were at 
higher risk for lumbar osteoporosis. Children with SLE are 
also at a higher risk of developing osteoporosis, considering 
that long-term use of hormones may affect the growth of 
their normal peak bone mass [57]. The causes of osteoporosis 
in SLE are very complex, including disease factors, drug 
influencing	factors	(glucocorticoid)	and	renal	damage,	etc.,	
and defective osteogenic differentiation of mesenchymal 
stem cells in SLE may also lead to osteoporosis [58-59]. 1,25- 
(OH) 2D3 can regulate calcium and phosphorus levels in 
patients with SLE through binding with vitamin D receptor 
(VDR), maintain mineral stability, thus promoting bone 
metabolism and bone transformation, and reducing the oc-
currence of osteoporosis in patients with SLE. Vitamin D 
can also regulate osteoblasts and osteoclasts.
5.5 VDR Gene Polymorphism and SLE
VDR is a nuclear receptor of 50 kDa, belonging to 
the second class of the steroid receptor family, similar 
to retinoic acid receptor and thyrotropin [60]. 1, 25 - (0 
h)2D binds to the nuclear VDR genome and determines 
genomic responses by regulating the transcription of 
certain genes [56].	VDR	is	synthesized	by	a	gene	located	
at position 12q13.1 on chromosome 12, known as VDR 
gene [57]. The gene is basically composed of 9 exons dis-
tributed in the 5 'promoter and the 3' regulatory region. In 
the latter region, a long 3 'untranslated region, known as 
the 3' untranslated region, is involved in the regulation of 
gene expression, in particular by regulating the stability 
of messenger RNA. VDR gene showed some polymor-
phisms in the promoter region between exons 2 and 9 in 
the 3 'translation region, especially in the promoter region 
around exons 1, F and C [61]. Polymorphism BSMI located 
in intron 8 and adenine - guanine replacement results (A-
G) [62]. Apai and Taqi polymorphisms were distributed in 
this region of the 3' gene. Polymorphic APAI is defined 
as thymine substitution (T-G) in intron 8, while polymor-
phic TAQI is defined as cytosine-thymine substitution 
(C-T),	 resulting	 in	codon	exchange	 (ATC→ATT),	but	
maintaining the same isoleucine amino acid [63]. Function-
al correlations of these polymorphisms were associated 
DOI: https://doi.org/10.30564/jhp.v3i1.2852
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with increased mRNA stability [64]. Foki polymorphism is 
caused by the substitution of cytosine-thymine (C-T) at the 
junction of intron 1 and exon 2, resulting in an additional 
start codon (ACG→ATG), three codons close to the tran-
scription start site. This polymorphism can be considered 
as an independent genetic marker because it does not 
appear to be in linkage imbalance with other VDR gene 
polymorphisms. An occurrence variant of Foki, defined as 
a mutation in F (Atg codon) resulting in complete produc-
tion of VDR protein (427 amino acids) [65]", and the muta-
tion	Foki,	defined	as	F	(codon	GCA),	starts	translating	at	
a different site to produce a slightly shorter VDR protein 
containing three fewer amino acids (424 amino acids). 
In vitro studies have shown that short proteins seem to 
have higher transcriptional activity than long proteins [66]. 
This may increase the function of VDR and thus alter the 
role of vitamin D in different cells and tissues. The effect 
of Foki polymorphism on the transcriptional activity of 
immunospecific	transcription	factors	 in	lymphocyte	pro-
liferation and immunocell protein synthesis suggests that 
Foki polymorphism is involved in immune regulation and 
immunoregulatory polymorphism [67].
In vitamin D transport and metabolism pathway, the SNP 
of VDR gene is associated with the susceptibility to severe 
respiratory syncytial virus infection, tuberculosis, asthma, 
systemic lupus erythematosus, colorectal tumor, melano-
ma, periodontitis, renal cell tumor, gout, multiple sclerosis, 
AIDS, Parkinson's disease and other diseases [68-70].
A large number of researchers have conducted exper-
iments on the relationship between BSMI polymorphism 
of VDR gene and SLE. In 2000, a study of 58 Japanese 
patients with SLE demonstrated a higher incidence of 
B/B genotypes compared with healthy controls (15.5 
vs. 5.7%,p<0.0001). In addition, a higher frequency of 
genotype B/B was found in nephrotic syndrome (61.5% 
vs. 35.7%,p<0.0034) in nephrotic patients [67]. In 2002, 
Chinese authors studied 47 patients with systemic lupus 
erythematosus and 90 healthy controls and found a higher 
B allele frequency in patients with systemic lupus ery-
thematosus (39.4% vs. 8.3%,OR=0.74, P <0.0001) [71]. 
A study of 101 Thai and 60 Iranian patients in 2006 and 
2010, respectively, found no association between BSMI 
polymorphisms and SLE or clinical and laboratory mani-
festations of the disease. In 2002, a study assessed FOKI 
polymorphisms in 52 patients with SLE and 90 healthy 
controls	and	found	no	significant	differences	in	allele	and	
genotype frequencies [72]. In 2010, a meta-analysis was 
published that found no significant Foki polymorphism. 
However, due to the small number of studies included, 
these results should be interpreted with caution, and they 
apply only to European and Asian ethnic groups [73]. A 
case-control	study	conducted	in	Brazil	also	 investigated	
the association between BSMI and Foki VDR gene poly-
morphism and susceptibility to SLE in 195 patients of 
European or African origin and 201 control patients. The 
results showed no association between BSMI and Foki 
VDR gene polymorphisms and SLE susceptibility. In 
this study, the mean serum level of 25-(0H)D in patients 
with SLE was 25.51±11.43 ng/ml. 25-(0H)D level in F/
F genotype patients was significantly higher than that 
in F/F genotype patients (31.6±14.1 vs 23.0±9.2 ng/ml, 
P <0.004). Although there is no significant association 
between FOKI polymorphism and SLE, the authors sug-
gest that FOKI polymorphism has an important effect on 
vitamin D metabolism in patients with SLE [71], BSMI and 
Foki VDR polymorphisms have recently been found in 
Chinese	patients.	The	frequency	of	homozygous	F/F	was	
higher in SLE patients than in controls (42.8 vs 25.4%, 
P =0.001). Seritis, anti-dsDNA antibodies, anti-Sm anti-
bodies, and anti-hiprotein antibodies in SLE patients with 
homozygous	F/F	and	heterozygous	F/F	were	higher	than	
those	in	SLE	patients	with	homozygous	F/F.	Patients	with	
SLE show a marked increase in the frequency of the B al-
lele, which is associated with lupus nephritis and with the 
production of anti-nucleosome antibodies [74].
6. Conclusions
At present, a large number of studies have explored the 
relationship	between	vitamin	D	deficiency	and	the	occur-
rence and development of SLE disease, but most of the 
studies on its mechanism remain at the cellular level, and 
a few involve genetic level. However, with the deepening 
of	the	research	on	SLE,	it	is	not	difficult	to	find	that	genet-
ic polymorphism of genes plays a non-negligible role in 
the occurrence and development of SLE. As an important 
pathway of vitamin D production, vitamin D metabolic 
pathway has a direct impact on vitamin D level, which 
further affects the occurrence and development of some 
diseases, especially autoimmune diseases (such as SLE). 
To sum up, in view of the vitamin D in SLE properties 
of calcium phosphate, immunity adjustment, system and 
SLE and VDR gene polymorphism, the correlation of 
atherosclerosis, improve the level of 1, 25 - (OH) 2 d3 to 
improve SLE patients with osteoporosis, disease activity, 
atherosclerosis, cardiovascular disease and clinical symp-
toms may play a role, but the kinds of vitamin D sup-
plements, dose and treatment remains to be more large-
scale	clinical	trials	research	further	defined.	It	remains	to	
be further investigated whether vitamin D and VDR can 
reduce or even replace hormone and immunosuppressive 
therapy, and whether adequate vitamin D supplementation 
can prevent the occurrence of SLE [75].
DOI: https://doi.org/10.30564/jhp.v3i1.2852
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